Opportunity
SAM #HT9427-27-NOI-701
Sole-source modification for FDA-required EZPLAZ clinical trial work
Buyer
Defense Health Agency
Posted
November 17, 2026
Respond By
November 23, 2026
Identifier
HT9427-27-NOI-701
NAICS
541715
The Defense Health Agency plans a sole-source contract modification for the EZPLAZ clinical trial and is inviting capability statements from other interested firms. - Agency and office: Defense Health Agency Contracting Activity, for the Portfolio Acquisition Executive Medical Products’ Warfighter Protection and Acute Care Project Management Office. - Intended contractor: Westat Inc.; the notice proposes modifying its existing award on a sole-source basis. - Work: Revise the EZPLAZ clinical trial design to address FDA recommendations and conduct a Good Clinical Practices-compliant study evaluating EZPLAZ and conventional plasma in adult patients to support FDA approval. - Sole-source rationale: Westat developed the current trial protocol and Statistical Analysis Plan and conducted the Phase 1 trial used for EZPLAZ licensure. - Response deadline: Capability statements are due by email by 2:00 PM local time on November 23, 2026. - Not specified: Quantities, part numbers, contract value, and period of performance.
Description
The Defense Health Agency Contracting Activity, on behalf of Portfolio Acquisition Executive for Medical Products, Warfighter Protection and Acute Care Project Management Office, intends to issue a contract modification on a sole-source basis with Westat Inc. 1600 Research Blvd. Rockville, MD 20850. This modification will enable Westat Inc. to modify the current clinical trial design to comply with FDA recommendations and to conduct the Good Clinical Practices (GCP) compliant clinical trial in accordance with U.S. Food and Drug Administration’s requirements for EZPLAZ™ approval.